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Dr Carlos A. Mestres (Barcelona, Spain). I have to disclose
that I am on the advisory board for Novartis Pharma and I have
done temporary consulting work for Edwards Lifesciences and
St Jude Medical in Europe.
Dr Zenati, as you know very well, the ROOBY Trial concluded
that at 1-year follow-up, patients undergoing off-pump CABG had
worse composite outcomes and poorer graft patencies than those
undergoing on-pump CABG. More interestingly, in your study,
when EVH was compared with OVH, 1-year patency was signifi-
cantly lower and revascularization rate significantly higher for
EVH.
Despite the proven advantages of EVH relative to OVH in terms
of wound complications and cosmesis, your data incorporated in-
formation showing that 1-year graft patency might be compro-
mised with endoscopic harvesting. Previous studies that included
smaller populations and angiography performed within the first
6 postoperative months did not show differences in patency.
Your data support a nonrandomized study showing worse out-
comes with EVH, and generally speaking it appears that SVG fail-
ure is higher with EVH, as also shown in a recent meta-analysis. In
addition, your patient population seems to be a good representa-
tion of ‘‘real life,’’ at least on the male side.
Reduced graft patency with EVH could be related to intrao-
perative trauma, which is inherent in the technique. There isThe Journal of Thoracic and Caalso information suggesting that EVH may impair endothelial
function.
The eventual implications of your study, in combinationwith the
available information on graft patency related to the harvesting
technique, could have potential impact on clinical practice and per-
haps relegate EVH and its association with off-pump surgery to the
suboptimal side in terms of long-term results. Your study appears to
be sufficiently poweredwhen compared to previous studies to draw
meaningful conclusions, despite a number of limitations that you
clearly addressed in your presentation and also in your manuscript.
Finally, before proceeding with my questions, I obviously have
to thank you for this significant and controversial piece of informa-
tion and the opportunity for advanced manuscript review and the
Association for the privilege of the discussion.
I have basically 3 questions for you. First, do you have informa-
tion about which were the territories with the highest occlusion
rate? If so, did that have a clinical impact on your patients?
Dr Zenati. Thank you, DrMestres, for your kind comments and
your question. Regarding the distribution of the SVGs and relative
patency as related to the harvesting technique, the right coronary
distribution, interestingly enough, did not show any difference in
terms of patency whether the conduit harvest was endoscopic or
open. The patency was 87.5% for EVH and 85.6% for OVH.
The difference was not statistically significant. When we looked
at the diagonal and obtuse marginal coronary arteries, the patency
was significantly higher for both targets when the harvest was
open. Patency was 69.7% in the obtuse marginal branch with
EVH, versus 82.9% with OVH.
Dr Mestres. Second, considering that a limitation is that you
did not randomly assign the harvesting technique, I find some
differences with especially the PREVENT trial, because that was
organized in the early phases of the learning curve with harvesting
techniques, whereas your trial was, of course, more recent in terms
of chronology. So, would you suggest that going through the learn-
ing curve in harvesting on an endoscopic basis is not a major prob-
lem in this trial?
Dr Zenati. You raise the issue of experience with harvesting,
and our trial does cover a more recent period than did the PRE-
VENT subanalysis. As we saw, the penetration of EVH technique
in the United States at the beginning of the ROOBY Trial in 2002
was probably less than 10%, rising almost exponentially to about
76% in 2008.Wewere not able to account for the effect of the level
of experience or the volume of procedures performed by the prac-
titioner who harvested the SVGs, however, because these data
were not collected.
Dr Mestres. Third, what is your current antithrombotic ther-
apy? Also, assuming that EVH represents basically induced endo-
thelial trauma, do you think that a more intense antithrombotic
regimen would be of any help?
Dr Zenati. You raise a very important point about the perioper-
ative antithrombotic approach in relationship to the potential for
increased endothelial damage during the harvest. Aspirin use
was ubiquitous in this study, and about 30% of patients also
received clopidogrel. The CASCADE trial was just presented
last fall at the American Heart Association, however, and its results
were negative in terms of the ability of the dual antiplatelet to im-
prove graft patency. This is something we need to reassess, and po-
tentially we need to include consideration of pharmacogenomicsrdiovascular Surgery c Volume 141, Number 2 343
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rel. On top of that, there is the issue of heparin at the beginning of
harvest, which has been shown in some series to affect graft
failure, but these data were not collected in this study and should
be in the future.
Dr Mestres. Thank you very much for this important contribu-
tion.
Dr Omar Lattouf (Atlanta, Ga). Dr Zenati, thank you for your
presentation. The points that you raise have significant medicole-
gal impact for those of us who use EVH. First, in defense of EVH, I
have to say that the data that you have presented did not take into
account any technical issues that were encountered at the time of
vein harvest either way and were not recorded. Second, we do344 The Journal of Thoracic and Cardiovascular Surgnot know the starting point for the conduit patency documented
by angiography, coronary ultrasonography, or flow patencies. If
you do have those data, can you share them with us, please?
Dr Zenati. Thank you. Regarding the technical issue, as I indi-
cated, a limitation of the study is that device-related or experience
issues may have affected outcomes, and these data unfortunately
were not collected, so I cannot comment on that. I believe that
future studies should consider device-related variables very seri-
ously, because the EVH technique is improving and evolving.
With respect to the timing of the failure of the grafts, most
(more than 90%) were protocol angiographies. So the graft could
have been closed at an earlier stage, and that is unfortunately
difficult to evaluate and comment on.ery c February 2011
